CSIMarket
 


Integrated Biopharma Inc  (INBP)
Other Ticker:  
 

Integrated Biopharma Inc's Leverage Ratio

INBP's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 18.05%, Leverage Ratio fell to 0.41, below the Integrated Biopharma Inc's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the first quarter 2023, 226 other companies have achieved lower Leverage Ratio than Integrated Biopharma Inc in the I Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the forth quarter 2023 from 838 to 861 .

Explain Leverage Ratio?
Who are INBP Customers?
What are INBP´s Total Liabilities?


INBP Leverage Ratio (Sep 30 2023)
I. Quarter
(Jun 30 2023)
IV. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
II. Quarter
(Sep 30 2022)
I. Quarter
Y / Y Equity Change 1.42 % 1.54 % 10.4 % 16.07 % 25.05 %
Y / Y Total Liabilities Change 0.17 % -1.57 % -24.09 % -32.73 % -18.02 %
Leverage Ratio MRQ 0.41 0.35 0.43 0.4 0.42
INBP's Total Ranking # 861 # 838 # 989 # 733 # 1000
Seq. Equity Change 0.13 % 0.64 % 0.48 % 0.17 % 0.25 %
Seq. Total Liabilities Change 18.05 % -19.28 % 9.99 % -4.43 % 16 %



Leverage Ratio first quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 227
Healthcare Sector # 403
Overall Market # 861


Leverage Ratio Statistics
High Average Low
100.15 9.67 0.35
(Sep 30 2018)   (Jun 30 2023)




Financial Statements
Integrated Biopharma Inc's Equity $ 19 Millions Visit INBP's Balance sheet
Integrated Biopharma Inc's Total Liabilities $ 8 Millions Visit INBP's Balance sheet
Source of INBP's Sales Visit INBP's Sales by Geography


Cumulative Integrated Biopharma Inc's Leverage Ratio

INBP's Leverage Ratio for the trailling 12 Months

INBP Leverage Ratio

(Sep 30 2023)
I. Quarter
(Jun 30 2023)
IV. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
II. Quarter
(Sep 30 2022)
I. Quarter
Y / Y Equity TTM Growth 1.42 % 1.54 % 10.4 % 16.07 % 25.05 %
Y / Y Total Liabilities TTM Growth 0.17 % -1.57 % -24.09 % -32.73 % -18.02 %
Leverage Ratio TTM 0.4 0.4 0.4 0.45 0.51
Total Ranking TTM # 464 # 812 # 872 # 948 # 1199
Seq. Equity TTM Growth 0.13 % 0.64 % 0.48 % 0.17 % 0.25 %
Seq. Total Liabilities TTM Growth 18.05 % -19.28 % 9.99 % -4.43 % 16 %


On the trailing twelve months basis Despite of the net new borrowings of 18.05% during the twelve months period ending in I Quarter 2023 Integrated Biopharma Inc has managed to unchanged Leverage Ratio in the I Quarter 2023 to 0.4, below Integrated Biopharma Inc's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry INBP recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has deteriorated during the twelve months ending in the I Quarter 2023, compared to the prior period, from 5 to 5.

Explain Leverage Ratio?
Who are INBP Customers?
What are INBP´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 861


trailing twelve months Leverage Ratio Statistics
High Average Low
20.38 3.56 0.39
(Jun 30 2019)   (Dec 31 2023)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Scpharmaceuticals Inc   1.13 $ 55.404  Millions$ 49.146  Millions
Eyenovia inc   1.12 $ 17.645  Millions$ 15.780  Millions
Johnson and Johnson  1.11 $ 79,025.000  Millions$ 71,228.000  Millions
2seventy Bio Inc   1.09 $ 334.384  Millions$ 306.422  Millions
Ani Pharmaceuticals Inc  1.07 $ 460.053  Millions$ 429.861  Millions
Zevra Therapeutics Inc   1.06 $ 71.512  Millions$ 67.470  Millions
Neubase Therapeutics inc   1.04 $ 9.485  Millions$ 9.137  Millions
Actinium Pharmaceuticals Inc   1.03 $ 44.839  Millions$ 43.583  Millions
Nighthawk Biosciences inc   1.01 $ 33.623  Millions$ 33.447  Millions
Virpax Pharmaceuticals Inc   1.00 $ 6.533  Millions$ 6.506  Millions
Royalty Pharma Plc  1.00 $ 9,614.891  Millions$ 9,585.097  Millions
Avalo Therapeutics Inc   0.99 $ 14.575  Millions$ 14.695  Millions
Bio path Holdings inc   0.99 $ 2.496  Millions$ 2.525  Millions
Lexicon Pharmaceuticals Inc   0.98 $ 136.969  Millions$ 139.510  Millions
Gri Bio Inc   0.98 $ 2.177  Millions$ 2.227  Millions
Assertio Holdings inc   0.97 $ 187.155  Millions$ 192.873  Millions
Entrada Therapeutics Inc   0.97 $ 238.370  Millions$ 246.663  Millions
Tg Therapeutics Inc   0.95 $ 156.776  Millions$ 164.769  Millions
Pieris Pharmaceuticals Inc   0.95 $ 28.866  Millions$ 30.510  Millions
Spero Therapeutics Inc   0.92 $ 49.276  Millions$ 53.705  Millions
Unity Biotechnology Inc   0.91 $ 33.064  Millions$ 36.206  Millions
Kiora Pharmaceuticals Inc  0.87 $ 7.085  Millions$ 8.104  Millions
Igm Biosciences Inc   0.87 $ 220.488  Millions$ 253.862  Millions
Eton Pharmaceuticals Inc   0.87 $ 14.634  Millions$ 16.892  Millions
Verastem inc   0.86 $ 71.814  Millions$ 83.180  Millions
Onconova Therapeutics inc   0.86 $ 12.521  Millions$ 14.517  Millions
Cryoport inc   0.86 $ 463.128  Millions$ 537.528  Millions
Pulmatrix Inc   0.85 $ 16.889  Millions$ 19.881  Millions
Pacira Biosciences inc   0.85 $ 702.911  Millions$ 831.551  Millions
Aptevo Therapeutics Inc   0.84 $ 12.411  Millions$ 14.718  Millions

Date modified: 2023-11-12T07:44:36+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com